Archive | September, 2016

May cannabinoids prevent the development of chemotherapy-induced diarrhea and intestinal mucositis? Experimental study in the rat.

2016 Sep 30. doi: 10.1111/nmo.12952. [Epub ahead of print] Abalo R1,2,3,4, Uranga JA5,6,7, Pérez-García I5, de Andrés R5, Girón R5,6,8,7, Vera G5,6,8,7, López-Pérez AE7,9, Martín-Fontelles MI5,6,8,7. Author information Abstract BACKGROUND: The antineoplastic drug 5-fluoruracil (5-FU) is a pirimidine analog, which frequently induces potentially fatal diarrhea and mucositis. Cannabinoids reduce gastrointestinal motility and secretion and might prevent 5-FU-induced gut adverse effects. Here, we asked whether cannabinoids may […]

Anandamide Suppresses Proinflammatory T Cell Responses In Vitro through Type-1 Cannabinoid Receptor-Mediated mTOR Inhibition in Human Keratinocytes.

 2016 Sep 30. pii: 1500546. [Epub ahead of print] Chiurchiù V1, Rapino C2, Talamonti E1, Leuti A1, Lanuti M3, Gueniche A4, Jourdain R4, Breton L4, Maccarrone M5. Author information Abstract The endocannabinoid system comprises cannabinoid receptors 1 and 2 (CB1 and CB2), their endogenous ligands, anandamide (AEA) and 2-arachidonoylglycerol, and metabolic enzymes of these ligands. The endocannabinoid system has recently been implicated in the regulation of […]

Medical cannabis – the Canadian perspective.

Journal List > J Pain Res > v.9; 2016 > PMC5053383 J Pain Res. 2016; 9: 735–744.  Published online 2016 Sep 30. doi:  10.2147/JPR.S98182 PMCID: PMC5053383 Gordon D Ko,1,2 Sara L Bober,1 Sean Mindra,3 and  Jason M Moreau1 Author information ► Copyright and License information ► Go to: Abstract Cannabis has been widely used as a medicinal agent in Eastern medicine with earliest evidence in ancient Chinese practice dating back to […]

Δ9-THC Intoxication by Cannabidiol-Enriched Cannabis Extract in Two Children with Refractory Epilepsy: Full Remission after Switching to Purified Cannabidiol.

 2016 Sep 30;7:359. eCollection 2016. Crippa JA1, Crippa AC2, Hallak JE1, Martín-Santos R3, Zuardi AW1. Author information Abstract Animal studies and preliminary clinical trials have shown that cannabidiol (CBD)-enriched extracts may have beneficial effects for children with treatment-resistant epilepsy. However, these compounds are not yet registered as medicines by regulatory agencies. We describe the cases of two children with […]

Cannabinoid Buccal Spray for Chronic Non-Cancer or Neuropathic Pain: A Review of Clinical Effectiveness, Safety, and Guidelines [Internet].

 Canadian Agency for Drugs and Technologies in Health; 2016 Sep. CADTH Rapid Response Reports. Excerpt Chronic pain is a complex, severe and debilitating condition which can lead to a considerable reduction in function and quality of life. Patients may present with different forms of chronic pain resulting from a number of identifiable causes, including pain […]

β-caryophyllene and β-caryophyllene oxide-natural compounds of anticancer and analgesic properties.

2016 Sep 30. doi: 10.1002/cam4.816. [Epub ahead of print] Fidyt K1,2, Fiedorowicz A1, Strządała L1, Szumny A2. Author information Abstract Natural bicyclic sesquiterpenes, β-caryophyllene (BCP) and β-caryophyllene oxide (BCPO), are present in a large number of plants worldwide. Both BCP and BCPO (BCP(O)) possess significant anticancer activities, affecting growth and proliferation of numerous cancer cells. Nevertheless, their antineoplastic […]

Interpretation of Workplace Tests for Cannabinoids.

2016 Sep 29. [Epub ahead of print] Kulig K1. Author information Abstract Workplace urine drug testing for an inactive THC metabolite is common in both federally regulated and non-regulated drug testing. A positive result does not document impairment, or even recent use, when impairment is likely the most important parameter being searched for by the […]

Cortical and spinal excitability in patients with multiple sclerosis and spasticity after oromucosal cannabinoid spray.

2016 Nov 15;370:263-268. doi: 10.1016/j.jns.2016.09.054. Epub 2016 Sep 28. Squintani G1, Donato F2, Turri M3, Deotto L2, Teatini F3, Moretto G2, Erro R4. Author information Abstract BACKGROUND: Delta-9-tetrahydrocannabinol and cannabidiol (THC:CBD) oromucosal spray (Sativex®) has been recently approved for the management of treatment-resistant multiple sclerosis (MS) spasticity. Although the symptomatic relief of Sativex® on MS-spasticity has been consistently demonstrated, the pathogenetic […]

Cannabidiol Prevents Motor and Cognitive Impairments Induced by Reserpine in Rats.

 2016 Sep 28;7:343. eCollection 2016. Peres FF1, Levin R1, Suiama MA1, Diana MC1, Gouvêa DA1, Almeida V1, Santos CM1, Lungato L2, Zuardi AW3, Hallak JE3, Crippa JA3, Vânia D2, Silva RH4, Abílio VC1. Author information Abstract Cannabidiol (CBD) is a non-psychotomimetic compound from Cannabis sativa that presents antipsychotic, anxiolytic, anti-inflammatory, and neuroprotective effects. In Parkinson’s disease patients, CBD is able to attenuate the psychotic symptoms induced by L-DOPA and to improve […]

Near infrared spectroscopy combined with chemometrics for growth stage classification of cannabis cultivated in a greenhouse from seized seeds.

2016 Sep 22;173:318-323. doi: 10.1016/j.saa.2016.09.040. [Epub ahead of print] Borille BT1, Marcelo MC2, Ortiz RS3, Mariotti KC4, Ferrão MF2, Limberger RP4. Author information Abstract Cannabis sativa L. (cannabis, Cannabaceae), popularly called marijuana, is one of the oldest plants known to man and it is the illicit drug most used worldwide. It also has been the subject of increasing discussions from […]